Large-pore sba-15 functionalized with tert-butylamine: a novel and efficient nanoscale delivery system of cyclophosphamide

JORGELINA CUSSA; JULIANA M. JUÁREZ; LORENA P. RIVOIRA; MARCOS B. GÓMEZ COSTA

Cancún

Congreso; XXXII International Materials Research Congress (IMRC 2024).; 2024

IMRC

In this work, we report the successful synthesis of the LP-SBA-15 TBA/Cyclophosphamide (CP)nanocomposite. The resulting system has a high drug reservoir potential to successfully embed and control CP delivery, thus achieving the desired treatment efficacy. Controlled drug delivery systems operate effectively using the correct carrier/host design that respects the physicochemical characteristics of the drug. LP-SBA-15 shows exceptional qualities as a new host for cyclophosphamide (CP) delivery due to its low toxicity, high biocompatibility, and biodegradability in vivo. Cyclophosphamide is a phosphoramide-derived alkylating compound currently used for treating autoimmune diseases and slowing or restraining cancer cell growth. LP-SBA-15 was synthesized and functionalized using 0%–15%–25% tert-Butylamine (TBA) to incorporate the drug. The composite was characterized by XRD, N2 physisorption, UV-VIS, and FTIR spectroscopy. Absorption and release of CP were assessed by UV-VIS spectrophotometry. As CP is absorbed at acidic pH and partially absorbed at neutral pH, release assays were performed initially in 0.1 M HCL, pH 1 (simulating gastric fluid), and subsequently in neutral phosphate buffered saline pH 7 (mimicking intestinal fluid). This allowed not only absorption and controlled release with particularly promising results, but also activity and safety of the delivery system, encapsulating the CP in a mesoporous silica network, with no side effects on the stomach mucosa, as in direct administration of CP. The release mechanism from the functionalized LP-SBA-15 matrix was evaluated by fitting experimental data with different mathematical models. The Ritger–Peppas, Weibull, and First-Order models were the most appropriate, as confirmed by the coefficient of determination R2 and other statistics. We designed LPSBA- 15 functionalized with 15%TBA as a suitable system that achieves a moderate initial release rate and maintains a constant rate over long periods, enabling the nanodrug (CP) to concentrate on tumor tissue and not on normal cells while simultaneously reaching adequate levels over time and avoiding harmful side effects due to their deposition.